Patient characteristics
| UPN . | Age, y/sex . | Ethnicity . | Disease . | Donor . | Donor match (mismatched loci) . | GVHD prophylaxis . | Days after HSCT when CTL is infused . | Cell dose . | Immune suppression at time of CTL infusion . | GVHD after CTLs . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1216 | 4/F | White | AML relapse | MUD | 9/10 (HLA-A) | Alemtuzumab, FK506 and MTX | 104 | 5 × 106/m2 | None | None | Died 7 mo of relapse |
| 1217 | 3/M | White | AML CR2 | MUD | 9/10 (HLA-DQB1) | Alemtuzumab, FK506 and prednisone | 150 | 5 × 106/m2 | None | None | CCR 3.5 y |
| 1218 | 7/F | Black | NHL relapse | MUD | 9/10 (HLADQB1) | Alemtuzumab, FK506 and MTX | 134 | 5 × 106/m2 | None | None | CCR 3 y |
| 1244 | 13/F | Hispanic | MDS/PNH | HAPLO | 5/10 (HLA-A, B, Cw, DRB1, DQB1) | Alemtuzumab, and CD34 selection | 77 | 1.5 × 107/m2 | None | None | CCR 3 y |
| 1252 | 11/F | White | AML transformed from MDS | MUD | 10/10 | Alemtuzumab, CSA | 53 | 1.5 × 107/m2 | FK506 | None | CCR 3 y |
| 1265 | 9/M | White | Thalassemia | MUD | 8/10 (HLA-Cw, Cw) | Alemtuzumab, FK506 and MTX | 80 | 4.5 × 107/m2 | FK506 | None | CCR 3 y |
| 1287 | 4/M | White | CML accelerated phase | MUD | 10/10 | Alemtuzumab, FK506 and MTX | 40 | 4.5 × 107/m2 | FK506 | None | CCR 2.5 y |
| 1329 | 1/M | White | SCID | MUD | 10/10 | Alemtuzumab, CSA, prednisone | 60 | 1.35 × 108/m2 | CSA and prednisone | None | CCR 2 y |
| 1309 | 4/M | Hispanic | MDS | HAPLO | 8/10 (HLA-A, B) | Alemtuzumab, FK506, prednisone | 76 | 1.35 × 108/m2 | None | None | Alive in relapse 2.5 y |
| 1352 | 5/M | Hispanic | ALL CR1 | HAPLO | 7/10 (HLA-A, B, Cw) | Alemtuzumab, and CD34 selection | 95 | 1.35 × 108/m2 | None | None | CCR 2.5 y |
| 1358 | 12/M | Hispanic | ALL CR1 | HAPLO | 6/10 (HLA-A, Cw, DRB1, DRQ1) | Alemtuzumab, and CD34 selection | 86 | 1.35 × 108/m2 | None | None | CCR 2 y |
| 1377 | 3/F | Hispanic | ALL refractory | HAPLO | 5/10 (HLA-A, B, Cw, DRB1, DQB1) | Alemtuzumab, and CD34 selection | 77 | 1.35 × 108/m2 | None | None | Alive in relapse 2 y |
| 1406 | 10/M | Black | Secondary AML | HAPLO | 7/10 (HLA-A, B, Cw) | Alemtuzumab, and CD34 selection | 70 | 1.35 × 108/m2 | None | None | Died 10 mo of relapse |
| UPN . | Age, y/sex . | Ethnicity . | Disease . | Donor . | Donor match (mismatched loci) . | GVHD prophylaxis . | Days after HSCT when CTL is infused . | Cell dose . | Immune suppression at time of CTL infusion . | GVHD after CTLs . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1216 | 4/F | White | AML relapse | MUD | 9/10 (HLA-A) | Alemtuzumab, FK506 and MTX | 104 | 5 × 106/m2 | None | None | Died 7 mo of relapse |
| 1217 | 3/M | White | AML CR2 | MUD | 9/10 (HLA-DQB1) | Alemtuzumab, FK506 and prednisone | 150 | 5 × 106/m2 | None | None | CCR 3.5 y |
| 1218 | 7/F | Black | NHL relapse | MUD | 9/10 (HLADQB1) | Alemtuzumab, FK506 and MTX | 134 | 5 × 106/m2 | None | None | CCR 3 y |
| 1244 | 13/F | Hispanic | MDS/PNH | HAPLO | 5/10 (HLA-A, B, Cw, DRB1, DQB1) | Alemtuzumab, and CD34 selection | 77 | 1.5 × 107/m2 | None | None | CCR 3 y |
| 1252 | 11/F | White | AML transformed from MDS | MUD | 10/10 | Alemtuzumab, CSA | 53 | 1.5 × 107/m2 | FK506 | None | CCR 3 y |
| 1265 | 9/M | White | Thalassemia | MUD | 8/10 (HLA-Cw, Cw) | Alemtuzumab, FK506 and MTX | 80 | 4.5 × 107/m2 | FK506 | None | CCR 3 y |
| 1287 | 4/M | White | CML accelerated phase | MUD | 10/10 | Alemtuzumab, FK506 and MTX | 40 | 4.5 × 107/m2 | FK506 | None | CCR 2.5 y |
| 1329 | 1/M | White | SCID | MUD | 10/10 | Alemtuzumab, CSA, prednisone | 60 | 1.35 × 108/m2 | CSA and prednisone | None | CCR 2 y |
| 1309 | 4/M | Hispanic | MDS | HAPLO | 8/10 (HLA-A, B) | Alemtuzumab, FK506, prednisone | 76 | 1.35 × 108/m2 | None | None | Alive in relapse 2.5 y |
| 1352 | 5/M | Hispanic | ALL CR1 | HAPLO | 7/10 (HLA-A, B, Cw) | Alemtuzumab, and CD34 selection | 95 | 1.35 × 108/m2 | None | None | CCR 2.5 y |
| 1358 | 12/M | Hispanic | ALL CR1 | HAPLO | 6/10 (HLA-A, Cw, DRB1, DRQ1) | Alemtuzumab, and CD34 selection | 86 | 1.35 × 108/m2 | None | None | CCR 2 y |
| 1377 | 3/F | Hispanic | ALL refractory | HAPLO | 5/10 (HLA-A, B, Cw, DRB1, DQB1) | Alemtuzumab, and CD34 selection | 77 | 1.35 × 108/m2 | None | None | Alive in relapse 2 y |
| 1406 | 10/M | Black | Secondary AML | HAPLO | 7/10 (HLA-A, B, Cw) | Alemtuzumab, and CD34 selection | 70 | 1.35 × 108/m2 | None | None | Died 10 mo of relapse |
UPN indicates unique patient number; F, female; M, male; GVHD, graft-versus-host disease; CTL, cytotoxic T lymphocyte; HSCT, hematopoieitic stem cell transplantation; AML, acute myeloid leukemia; MUD, matched unrelated donor; HLA, human leukocyte antigen; alemtuzumab, anti-CD52 monoclonal antibody; FK506, tacrolimus; MTX, methotrexate; CCR, continuous complete remission; NHL, non-Hodgkin lymphoma; MDS, myelodysplastic syndrome; PNH, paroxysmal nocturnal hemoglobinuria; HAPLO, mismatched related haploidentical donor; CML, chronic myeloid leukemia; SCID, severe combined immunodeficiency; ALL, acute lymphoblastic leukemia; and CR, complete remission.